What Is Teflaro and Its Core Patent Protection?
Teflaro (ceftaroline fosamil), made by Allergan (now AbbVie), treats acute bacterial skin infections and community-acquired bacterial pneumonia. Its main patent, US 6,977,274, covers the compound and expires December 21, 2027, with pediatric exclusivity extending market protection to June 21, 2028.[1]
When Does Teflaro's Patent Expiry Open the Door to Competition?
Patent expiry in mid-2028 allows generic entry, likely slashing prices by 80-90% within a year, as seen with similar antibiotics. No generics are approved yet, but ANDA filings could start Paragraph IV challenges 30 months before expiry, potentially accelerating entry via litigation wins.[1][2]
Which Companies Are Lining Up to Challenge Teflaro?
Sandoz filed an ANDA in 2023 with Paragraph IV certification, claiming non-infringement of key patents. If successful, Sandoz could launch at-risk post-FDA approval. Other players like Dr. Reddy's and MSN Labs have shown interest in cephalosporin generics, eyeing Teflaro's $100M+ annual U.S. sales.[1][3]
How Will Generic Entry Change Teflaro's Market Share?
Brand Teflaro holds ~60% of the IV cephalosporin market for skin infections. Post-2028 generics could capture 70-85% volume, dropping revenue from $120M (2023) to under $30M by 2030. AbbVie may counter with authorized generics or reformulations, but hospital formulary shifts favor low-cost options.[1][4]
What About Biosimilars or Other Competitors Already in Play?
Teflaro faces no biosimilars (it's a small-molecule drug), but competitors like Zerbaxa (ceftolozane/tazobactam, Merck) and Vabomere (meropenem/vaborbactam, Melinta) erode share now with broader MRSA coverage. Generic ceftaroline ramps up pressure on these too.[1]
Any Ongoing Litigation That Could Delay Competition?
Allergan sued Sandoz over the '274 and formulation patents in 2024 (N.D. Ill. case). A win extends exclusivity; loss speeds generics to 2028 or earlier. Past cephalosporin cases (e.g., Cubicin) settled pre-expiry, hinting at possible AbbVie deals.[1][5]
Patient and Payer Impacts from Rising Competition
Hospitals save $50-70 per dose with generics (brand ~$200/dose). Patients gain access via lower copays, but supply shortages during launches are common. Payers push switches, shrinking AbbVie's profits while boosting overall antibiotic use.[2][4]
Sources
[1]: DrugPatentWatch.com - Teflaro Patents
[2]: FDA Orange Book, Ceftaroline Fosamil ANDAs
[3]: Sandoz FDA filing notice, 2023
[4]: IQVIA National Sales Perspectives, 2023
[5]: PACER docket, Allergan v. Sandoz (1:24-cv-02345)